Abstract: Metabolism of levodopa via the enzyme catechol-Omethyltransferase requires S-adenosylmethionine (SAM) as a methyl donor. SAM caused Parkinson disease (PD)-like symptoms in rodents. Therefore, SAM could contribute to a decreased efficacy of levodopa in the long term. SAM levels were significantly reduced in levodopa-treated PD patients, but they showed increased enzyme methionine adenosyl transferase (MAT) activity, which induces SAM synthesis from methionine (MET). This may result from a rebound increase of SAM production. The objective of the study was to demonstrate an effect of acute levodopa intake on SAM synthesis in the plasma of treated PD patients. The authors measured SAM, MET, and levodopa plasma concentrations in 13 levodopa-treated PD patients before and after application of 125 mg levodopa/benserazide. Plasma levels of SAM and levodopa significantly increased, but MET concentrations did not significantly decrease. The SAM increase after levodopa intake may exert both a certain antidepressant and cognitive function improving effect. This is often observed in untreated PD patients who receive levodopa for the first time, or in more advanced, fluctuating PD patients, when they turn from the OFF to the ON phase. Because SAM in higher dosages may also counteract the antiparkinsonian efficacy of levodopa according to animal trials, this SAM increase may hypothetically contribute to the onset of wearingoff phenomena and other clinical signs of limited efficacy of levodopa during long-term treatment with levodopa in PD patients.
P atients with Parkinson disease (PD) take levodopa with dopa decarboxylase inhibitors (DDI), such as carbidopa or benserazide, to reduce metabolism of levodopa in the periphery. A further, relevant degradation pathway is the conversion of levodopa to 3-O-methyldopa by the enzyme catechol-O-methyltransferase (COMT) in blood, peripheral tissue, and nigrostriatal neurons. COMT requires Mg 2+ as a cofactor and, as a methyl donor, S-adenosylmethionine (SAM), which is synthesized from adenosine triphosphate and methionine (MET).
1,2 SAM caused PD-like symptoms in rodents and therefore could contribute to an decreased efficacy of levodopa when it is administered to PD patients in a chronic fashion.
On the one hand, SAM levels were found to be significantly reduced in PD patients in comparison with control subjects. [2] [3] [4] On the other hand, PD patients showed increased catalytic activity of the enzyme methionine adenosyl transferase (MAT), which is responsible for the SAM synthesis. This may result from a rebound increase of SAM synthesis. This was tested by administering intraperitoneally saline or levodopa to mice and assaying for brain MAT activity. Compared with controls, levodopa (100 mg/kg) administrations, once daily or twice daily for a 4-day interval did not significantly change MAT activity. However, levodopa applications thrice daily for a duration of 4 or 8 days did significantly increase the activity of MAT by 21.38% and 28.37% respectively. A further trial in animals showed that levodopa induces activity of both enzymes MAT and COMT. Additionally the downturn in brain dopamine coincided with an increase in SAM and the 48-kDa MAT protein after 6 days. This occurrence of induction of MAT and COMT activity during treatment with levodopa in turn increases methylation and reduction of levodopa and dopamine, which may help cause the tolerance or the wearing-off effect developed in response to levodopa. 5 Moreover, this SAM increase may support induction of neuronal cell death via the apoptotic pathway. 6 The objective of the current trial was to demonstrate an effect of acute levodopa intake on concentrations of SAM and MET in plasma of chronic levodopa-treated PD patients.
SUBJECTS AND METHODS

Subjects
Thirteen PD patients (6 men, 7 women; mean age 6 SD, 64.23 6 11.29 years; range, 48-83 years; Hoehn & Yahr stage, 2.92 6 1.04; range, 1-4; chronic oral levodopa intake, 457.69 6 272.22 mg; range, 125-900 mg; benserazide, n = 11; carbidopa, n = 2) participated in this study. Their dopaminergic substitution therapy mainly consisted of levodopa/DDI and 1 dopamine agonist. No participant was previously exposed to neuroleptic drugs or any treatment known to affect the dopaminergic system. Exclusion criteria were clinical signs of dementia and any electrophysiologic or morphologic evidence (cranial CT scan or MR image) of additional CNS pathology exceeding PD. All subjects fulfilled clinical diagnostic UK Brain Bank criteria for PD. We excluded PD patients with metabolic disturbances (such as diabetes mellitus, hypertension, reduced levels of vitamin B6, cobalamin, and/or folic acid) or neurologic diseases other than PD.
Design
Each participant fasted and was off any medication for at least 8 hours before taking the first blood sample at 7 AM. Then the patients received 100 mg levodopa and 25 mg benserazide (Madopar, 125 mg). The second taking of blood samples was 30 minutes later. Adverse effects did not appear.
Blood samples
Three milliliters of blood was drawn with a separate syringe and discarded before taking each 10-mL specimen. We collected blood samples in EDTA test tubes containing 100 mL 0.5% sodium disulfite solution. The plasma obtained from rapid centrifugation was immediately frozen at -80°C until analysis within 14 days. Reverse-phase high-performance liquid chromatography (HPLC) in combination with electrochemical detection was used for the measurement of levodopa levels in plasma, which was diluted to a factor of 1:1.95 before assessment. 7 Determination of SAM and MET plasma levels was performed by HPLC. 4 
Statistics
The paired, two-sided t test of dependent samples was used for comparisons. Level of significance was P , 0.05. Linear regression was performed for correlation analysis.
Ethics
Informed consent was obtained from each subject. This study was approved by the local ethics committee.
RESULTS
Plasma levels of SAM (P = 0.008; Fig. 1 ) and levodopa (P = 0.002, Fig. 2 ) significantly increased. Mean MET concentrations 6 SD did not change significantly (7 
DISCUSSION
Acute oral levodopa administration caused increased plasma concentrations of levodopa and SAM in PD patients on a chronic levodopa/DDI regimen. Thus we confirm that an upregulation of MAT with a consecutive SAM increase occurs in PD patients after levodopa intake by circumstantial evidence. 1, 5, 8 One may assume, based on these former findings and our current results, that this levodopa-associated SAM increase also occurs centrally within the brain itself, due to the transfer of SAM over the blood-brain barrier, or both. This suggests that SAM may exert both a certain antidepressant and cognitive function improving effect in PD patients. 9, 10 This is often observed in the clinic-in particular, after levodopa intake in untreated PD patients, who receive levodopa for the first time, 11 or in more advanced, fluctuating PD patients, when they turn from the OFF to the ON phase. 12, 13 Because SAM is also the methyl donor for nicotinamide N-methylation and most other important methylation reactions, including that of DNA and RNA, such an observed modest SAM increase as seen in our trial may also contribute to detoxification processes.
14 However accumulation of SAM to excess toxic doses may induce tremor, rigidity, abnormal posture, and, in particular, hypokinesia in a dose-related fashion. 8, 15 Therefore it may also counteract the antiparkinsonian efficacy of levodopa to a certain extent and may contribute to the onset of wearingoff phenomena and other clinical signs of limited efficacy of levodopa during long-term treatment with levodopa.
The observed variability of increase of the plasma levodopa concentrations may result from various absorption patterns due to an altered gastrointestinal motility in our PD patients. 16 This may also contribute to the observed missing correlation of the levodopa plasma levels between both assessment points in contrast to the found significant relations in the case of SAM and MET.
There was no significant change in MET in our trial. This indicates that the SAM increase does not provoke a peripheral depletion of MET.
In conclusion, our study results show a modest increase of SAM plasma levels following oral levodopa intake in treated PD patients. This confirms earlier findings of a temporary MAT upregulation during chronic levodopa treatment in animals.
